Jasper Therapeutics Inc. reported a net loss of $18.7 million, or $1.13 per share, for the three months ended September 30, 2025. Research and development expenses were $14.4 million, while general and administrative expenses totaled $4.8 million. The company held $50.9 million in cash and cash equivalents as of September 30, 2025. During the quarter, Jasper completed a $30 million underwritten offering of common stock and warrants, extending its cash runway through the first half of 2026. Jasper continued enrollment in the BEACON and open-label extension studies for its briquilimab antibody therapy and provided updates on investigations into previously reported efficacy results. The Phase 2b study for chronic spontaneous urticaria is expected to begin in mid-2026.